Search Results
Found 1 results
510(k) Data Aggregation
(118 days)
MODIFICATION TO CARBON DIOXIDE-L3K ASSAY, CAT. NOS. 299-30, 299-17, 299-50, 299-80 AND 299-12
For the quantitative determination of carbon dioxide in serum and plasma. For IN VITRO diagnostic use.
The DCL Carbon Dioxide L3K® assay is an enzymatic procedure, employing phosphoenolpyruvate carboxylase (PEPC) (2) and a stabilized NADH analog (3), which is easy to use and applicable to routine laboratory instrumentation.
I am sorry, but the provided text is a letter from the FDA regarding a 510(k) premarket notification for a Carbon Dioxide-L3K Assay. It confirms the substantial equivalence of the device to legally marketed predicate devices and outlines regulatory requirements.
This document does not contain information about:
- Acceptance criteria and reported device performance in a table format.
- Sample sizes, data provenance, or details about test sets.
- Number and qualifications of experts for ground truth establishment.
- Adjudication methods.
- Results of multi-reader multi-case (MRMC) comparative effectiveness studies.
- Standalone algorithm performance.
- Type of ground truth used.
- Sample size for the training set or how ground truth for the training set was established.
Therefore, I cannot fulfill your request based on the provided input.
Ask a specific question about this device
Page 1 of 1